BCRX logo

BCRX

BioCryst Pharmaceuticals Inc.

$8.31
-$0.16(-1.89%)
48
Overall
--
Value
36
Tech
60
Quality
Market Cap
$1.80B
Volume
2.31M
52W Range
$6.02 - $11.31
Target Price
$16.82
Order:

Income Statement

MetricTrendChart
2015
Dec
2016
Dec
2017
Dec
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$48.3M$26.4M$25.2M$20.7M$48.8M$17.8M$157.2M$270.8M$331.4M$450.7M
Total Revenue
$6.3M$2.3M$25.2M$20.7M$48.8M$17.8M$157.2M$270.8M$331.4M$450.7M
COST OF GOODS SOLD
Cost of Revenue
$-1.4M$-2.3M$-1.1M--$3.7M$1.7M$7.3M$6.6M$4.5M$12.3M
GROSS PROFIT
Gross Profit
$46.9M$24.1M$-1.1M$20.7M$45.1M$16.1M$149.9M$264.2M$326.9M$438.2M
OPERATING EXPENSES
Operating Expenses
$86.3M$72.7M$81.5M$114.9M$144.6M$190.9M$327.6M$412.7M$430.5M$440.8M
Research & Development
$72.8M$61.0M$67.0M$84.9M$107.1M$123.0M$208.8M$253.3M$216.6M$174.6M
Research Expense
$72.8M$61.0M$67.0M$84.9M$107.1M$123.0M$208.8M$253.3M$216.6M$174.6M
Selling, General & Administrative
$13.0M$11.3M$13.9M$29.5M$37.1M$67.9M$118.8M$159.4M$213.9M$266.1M
Selling & Marketing Expenses
$13.0M$11.3M$13.9M----$6.6M$5.7M$14.9M$14.4M$13.6M
General & Administrative Expenses
$-664.0K$-721.0K$-617.0K$29.5M$37.1M$67.9M$118.8M$159.4M$213.9M$266.1M
Promotion & Advertising
$-103.0K--------$6.6M$5.7M$14.9M$14.4M$13.6M
Salaries & Wages
$-9.7M$-8.5M$-12.6M----$14.8M----$55.6M$65.4M
Depreciation & Amortization
$-180.0K$-483.0K$-704.0K$-770.0K$724.0K$748.0K$777.0K$1.4M$1.7M$1.2M
Depreciation & Amortization
$-180.0K$-483.0K$-704.0K$-770.0K$724.0K$748.0K$777.0K$1.4M$1.7M$1.2M
Amortization
$-439.0K$-558.0K$-876.0K$-885.0K$1.3M$2.4M--$816.0K$1.2M$1.8M
Other Operating Expenses
$528.0K$402.0K$560.0K$471.0K$375.0K$-1.0M$-1.5M$-4.1M$-825.0K$-353.0K
OPERATING INCOME
Operating income
$-39.4M$-48.6M$-82.6M$-94.2M$-99.5M$-174.8M$-177.7M$-148.4M$-103.7M$-2.5M
EBITDA
$-36.6M$-47.1M$-55.5M$-90.3M$-96.8M$-166.7M$-121.7M$-143.9M$-234.6M$12.8M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$5.2M$6.5M$8.6M$9.2M$11.9M$14.5M$59.3M$99.1M$201.0K$98.5M
Intinc
$535.0K$793.0K$1.0M$2.3M$1.9M------$15.8M$14.7M
Net Non-Operating Interest Income/Expense
$-4.7M$-5.7M$-7.5M$-6.9M$-11.9M$-14.5M$-59.3M$94.0M$15.8M$14.7M
Gain on Sale of Securities
$1.1M$-843.0K$-821.0K--------------
Other Income/Expense
$-1.1M$843.0K$-24.4M----$2.0M$-55.8M$-2.0M$29.0M--
Other Special Charges
----$25.2M----$-2.0M$55.8M--$-29.0M--
SPECIAL ITEMS
Special Income Charges
----------------$-1.5M--
Impairment of Capital Assets
----------------$1.5M--
PRE-TAX INCOME
EBIT
$-37.8M$-48.7M$-57.2M$-92.1M$-98.9M$-170.9M$-122.5M$-145.3M$-226.0M$11.6M
Pre-Tax Income
$-43.0M$-55.1M$-65.8M$-101.3M$-110.8M$-182.8M$-181.8M$-244.4M$-226.2M$-87.0M
INCOME TAX
Tax Provision
$-1.0M$-1.1M$-71.2M$-18.0K$-1.6M$-2.5M$2.3M$2.7M$310.0K$1.9M
NET INCOME
Net Income
$-43.0M$-55.1M$-65.8M$-101.3M$-108.9M$-182.8M$-184.1M$-247.1M$-226.5M$-88.9M
Net Income (Continuing Operations)
$-43.0M$-55.1M$-65.8M$-101.3M$-108.9M$-182.8M$-184.1M$-247.1M$-226.5M$-88.9M
Net Income (Discontinued Operations)
$-43.0M$-55.1M$-65.8M$-101.3M$-108.9M$-182.8M$-184.1M$-247.1M$-226.5M$-88.9M
Net Income (Common Stockholders)
$-43.0M$-55.1M$-65.8M$-101.3M$-108.9M$-182.8M$-184.1M$-247.1M$-226.5M$-88.9M
Normalized Income
----------$-185.4M----$-177.2M--
TOTALS
Total Expenses
$85.0M$70.4M$80.3M$114.9M$148.3M$192.6M$334.9M$419.3M$434.9M$453.0M
SHARE & EPS DATA
Average Shares Outstanding
$172.1M$73.5M$84.3M$103.3M$115.8M$537.7M$178.7K$185.9M$192.2M$206.7M
Average Shares Outstanding (Diluted)
$72.9M$73.7M$84.5M$103.2M$115.6M$167.3M$179.1M$185.9M$192.2M$206.7M
Shares Outstanding
$73.6M$74.0M$98.6M$110.2M$154.2M$177.2M$184.7M$188.5M$206.1M$209.0M
Basic EPS
$-0.25----$-0.98$-0.94$-1.09$-1.03$-1.33$-1.18$-0.43
Basic EPS (Continuing Operations)
------$-0.98$-0.94$-1.09$-1.03$-1.33$-1.18$-0.43
Diluted EPS
$-0.59$-0.75$-0.78$-0.98$-0.94$-1.09$-1.03$-1.33$-1.18$-0.43
Diluted EPS (Continuing Operations)
------------$-1.03$-1.33$-1.18$-0.43
OTHER METRICS
Acquired In Process Rn D Income
$39.6M------------------
Net Income From Other Gains Losses
--------$1.9M----------
Other Gand A
$-664.0K$-721.0K$-617.0K$29.5M$37.1M$67.9M$118.8M$159.4M$213.9M$266.1M
Rent And Landing Fees
$-664.0K$-721.0K$-617.0K--------------
Selling Expense
$13.0M$11.3M$13.9M--------------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2BCRX$8.31-1.9%2.31M
3
4
5
6

Get BioCryst Pharmaceuticals Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.